Ht-Logo-gigapixel-icon
Friday, November 22, 2024
Canada’s Politics and Government News Source Since 1989
Friday, November 22, 2024 | Latest Paper

Brett Skinner

Is drug price policy evidence-based or evidence-deficient?

Opinion | BY BRETT SKINNER | July 4, 2022
Policymakers tend to see the prices of innovative medicines, but not the value, and this has resulted in a huge bureaucracy built to control the cost of patented drugs, writes Brett Skinner. Photograph courtesy of Pixabay
Opinion | BY BRETT SKINNER | July 4, 2022
Opinion | BY BRETT SKINNER | July 4, 2022
Policymakers tend to see the prices of innovative medicines, but not the value, and this has resulted in a huge bureaucracy built to control the cost of patented drugs, writes Brett Skinner. Photograph courtesy of Pixabay
Opinion | BY BRETT SKINNER | July 4, 2022
Policymakers tend to see the prices of innovative medicines, but not the value, and this has resulted in a huge bureaucracy built to control the cost of patented drugs, writes Brett Skinner. Photograph courtesy of Pixabay
Opinion | BY BRETT SKINNER | July 4, 2022
Opinion | BY BRETT SKINNER | July 4, 2022
Policymakers tend to see the prices of innovative medicines, but not the value, and this has resulted in a huge bureaucracy built to control the cost of patented drugs, writes Brett Skinner. Photograph courtesy of Pixabay